Trigeminal Nerve Stimulation (TNS) for Pediatric ADHD: Current Evidence and Future Directions

What Is TNS?

Trigeminal Nerve Stimulation (TNS) is a non‑invasive neuromodulation technique delivering low‑level electrical stimulation to branches of the trigeminal nerve (via forehead patch) to modulate brain networks involved in attention and arousal.

Current Evidence in Pediatric ADHD

• 2018 Pilot Study (McGough et al.): 62 children (8–12 yrs), 4 weeks active TNS vs. sham. Significant improvement in ADHD‑RS scores (primary outcome) with active TNS.
• 2019 Open‑Label Extension: Sustained benefits with continued use.
• Limitations: Small samples, short duration, lack of long‑term safety data, no head‑to‑head vs. stimulants.

Potential Side Effects

Generally mild: forehead tingling/itching, headache, fatigue. No serious adverse events reported in trials.

Current Clinical Status

• FDA cleared (2019) for ADHD in children 7–12 years not on medication (Monarch eTNS System).
• Not a first‑line treatment; guideline‑recommended options (stimulants, behavior therapy) have stronger evidence.
• May be considered for families preferring non‑pharmacologic options or with contraindications to medication.

Future Research Needs

• Large, long‑term RCTs
• Combination studies (TNS + medication/therapy)
• Biomarkers to predict responders
• Cost‑effectiveness analyses

Conclusion

TNS shows promise as a non‑drug ADHD intervention but requires more robust evidence before broad adoption. Shared decision‑making with a specialist is essential.